TABLE 1.
Baseline characteristics of all patients diagnosed with peritoneal metastasis
| Baseline variables |
Right‐sided N = 4555 (57.4%) Median [IQR]/N(%) |
Left‐sided N = 3375 (42.6%) Median [IQR]/N (%) |
P value |
|---|---|---|---|
| Age at diagnosis, years | 70 [62‐78] | 69 [60‐77] | <.001 |
| Sex | <.001 | ||
| Male | 2102 (46.1) | 1833 (54.3) | |
| Female | 2453 (53.9) | 1542 (45.7) | |
| Year of diagnosis | .035 | ||
| 1995‐1999 | 410 (55.9) | 323 (44.1) | |
| 2000‐2004 | 530 (53.9) | 453 (46.1) | |
| 2005‐2009 | 1293 (57.1) | 970 (42.9) | |
| ≥2010 (2016) | 2322 (58.8) | 1629 (41.2) | |
| Location primary | N/A | ||
| Cecum | 2161 (47.4) | ||
| Ascending colon | 1186 (26.0) | ||
| Hepatic flexure | 487 (10.7) | ||
| Transverse colon | 721 (15.8) | ||
| Splenic flexure | 377 (11.2) | ||
| Descending colon | 353 (10.5) | ||
| Sigmoid colon | 2301(68.2) | ||
| Recto sigmoid | 344 (10.2) | ||
| pT‐stage primary | .225 | ||
| T1‐2 | 31 (0.7) | 30 (0.9) | |
| T3‐4 | 2364 (51.9) | 1675 (49.6) | |
| Unknown | 2160 (47.4) | 1670 (49.5) | |
| pN‐stage primary | <.001 | ||
| N0 | 268 (5.9) | 261 (7.7) | |
| N+ | 2039 (44.8) | 1358 (40.2) | |
| Unknown | 2248 (49.4) | 1756 (52.0) | |
| Extraperitoneal metastasis | <.001 | ||
| Yes | 2130 (46.8) | 1737 (51.5) | |
| No | 2425 (53.2) | 1638 (48.5) | |
| Mucinous histology | .894 | ||
| Yes | 923 (20.3) | 688 (20.4) | |
| No | 3632 (79.7) | 2687 (79.6) | |
| Differentiation | <.001 | ||
| Well | 112 (2.5) | 106 (3.1) | |
| Moderate | 1448 (31.8) | 1262 (37.4) | |
| Poor | 1276 (30.0) | 730 (21.6) | |
| Unknown | 1719(37.7) | 1277(37.8) | |
| CTx b | .082 | ||
| Yes | 2028 (44.5) | 1569 (46.5) | |
| No | 2527 (55.5) | 1806 (53.5) | |
| CRS‐HIPEC | .008 | ||
| Yes | 294 (6.5) | 270 (8.0) | |
| No | 4255 (93.4) | 3103 (91.9) | |
| Unknown | 6 (0.1) | 2 (0.1) |
a
CTx chemotherapy, CRS‐HIPEC cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
b
CTx either administered in the palliative setting or in neoadjuvant or adjuvant setting or both.